May 8, 2017 Dear Duchenne Families, Today we shared our plans for the launch of EMFLAZA™ (deflazacort), the first FDA-approved corticosteroid for Duchenne muscular dystrophy patients age 5 and […]
CureDuchenne is pleased to see the positive preliminary data from Capricor Therapeutics on their HOPE clinical trial in Duchenne muscular dystrophy. CureDuchenne Ventures helped fund this clinical trial to address […]
April 20, 2017 Dear Duchenne Community, Today we announced that we have completed our acquisition of Emflaza™ (deflazacort), the first FDA-approved, anti-inflammatory therapy for Duchenne Muscular Dystrophy (DMD) patients […]
(CureDuchenne letter to Anthem dated March 14) CureDuchenne believes that all those with Duchenne that have a treatment option available to them should have access to the drug. Our heart […]
We are happy to share the following letter to the Duchenne Community from Stu Peltz, CEO PTC Therapeutics. March 24, 2017 Dear Duchenne Community, We were very excited to […]
Here is a summary of today’s call with PTC’s Patient Advocacy and Commercial Teams Thank you PTC for hosting a call for advocacy leaders this morning to introduce the EMFLAZA […]
Haydee Bustos has a passion for helping kids, and through her experience as a physical therapist, she discovered an even deeper desire to help kids with Duchenne muscular dystrophy. […]
CureDuchenne is sharing an expanded and updated open letter to the Duchenne community from Marathon Pharmaceuticals. An Open Letter to the Duchenne Community Dear Members of the Duchenne Community: […]
CureDuchenne is sharing an expanded and updated open letter to the Duchenne community from Marathon Pharmaceuticals. An Open Letter to the Duchenne Community Dear Members of the Duchenne Community: […]
